Press Brake Specialist

Proto Labs (NYSE:PRLB) delivers strong Q2 CY2026 numbers, provides encouraging quarterly Revenue Guidance. Manufacturing services provider Proto Labs PRLB reported Q2 CY2026 results exceeding the market's revenue expectations, with sales up 10.6% year on year to $149.3 million. Guidance for next quarter's revenue was optimistic at $149 million at the midpoint, 2.2% above analysts' estimates. Its non-GAAP profit of $0.60 per share was 11.5% above analysts' consensus estimates. Proto Labs (PRLB) Q2 CY2026 Highlights: * Revenue: $149.3 million vs analyst estimates of $144.1 million (10.6% year-on-year growth, 3.6% beat) * Adjusted EPS: $0.60 vs analyst estimates of $0.54 (11.5% beat) * Adjusted EBITDA: $25.12 million vs analyst estimates of $23.53 million (16.8% margin, 6.8% beat) * Revenue Guidance for Q3 CY2026 is $149 million at the midpoint, above analyst estimates of $145.7 million * Adjusted EPS guidance for Q3 CY2026 is $0.60 at the midpoint, above analyst estimates of $0.51 * Operating Margin: 7.6%, up from 3.7% in the same quarter last year * Free Cash Flow Margin: 6.2%, similar to the same quarter last year * Market Capitalization: $1.79 billion "Through the first half of 2026, we have demonstrated that Protolabs can deliver strong financial performance while simultaneously transforming the business for the future," said President and Chief Executive Officer Suresh Krishna. Company Overview Pioneering the concept of online quoting and manufacturing for custom prototypes and low-volume production parts, Proto Labs PRLB offers injection molding, 3D printing, and sheet metal fabrication for manufacturers in various industries. Revenue Growth A company's long-term performance is an indicator of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Regrettably, Proto Labs's sales grew at a sluggish 4.4% compounded annual growth rate over the last five years. This was below our standard for the industrials sector and is a poor baseline for our analysis. Long-term growth is the most important, but within industrials, a half-decade historical view may miss new industry trends or demand cycles. Proto Labs's annualized revenue growth of 4.9% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. We can dig further into the company's revenue dynamics by analyzing its three most important segments: Injection Molding, CNC Machining, and 3D Printing, which are 35.9%, 47.1%, and 13.8% of revenue. Over the last two years, Proto Labs's Injection Molding(injection molds and parts) and CNC Machining(custom CNC-machined parts) revenues averaged year-on-year growth of 2.2% and 17.2% while its 3D Printing revenue (custom 3D-printed parts) averaged 2.3% declines. This quarter, Proto Labs reported year-on-year revenue growth of 10.6%, and its $149.3 million of revenue exceeded Wall Street's estimates by 3.6%. Company management is currently guiding for a 10.1% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 5.5% over the next 12 months, similar to its two-year rate. This projection is underwhelming and indicates its newer products and services will not accelerate its top-line performance yet. ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who's building AI, one company is already using it to print money. And nobody's paying attention. AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won't last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice. Operating Margin Operating margin is one of the best measures of profitability because it tells us how much money a company takes home after procuring and manufacturing its products, marketing and selling those products, and most importantly, keeping them relevant through research and development. Proto Labs's operating margin has been trending up over the last 12 months, leading to break even profits over the last five years. However, its large expense base and inefficient cost structure mean it still sports inadequate profitability for an industrials business. This result is surprising given its high gross margin as a starting point. Analyzing the trend in its profitability, Proto Labs's operating margin might have fluctuated slightly but has generally stayed the same over the last five years. This raises questions about the company's expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. This quarter, Proto Labs generated an operating margin profit margin of 7.6%, up 3.9 percentage points year on year. The increase was encouraging, and because its operating margin rose more than its gross margin, we can infer it was more efficient with expenses such as marketing, R&D, and administrative overhead. Earnings Per Share We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable. Proto Labs's flat EPS over the last five years was below its 4.4% annualized revenue growth. However, its operating margin didn't change during this time, telling us that non-fundamental factors such as interest and taxes affected its ultimate earnings. Like with revenue, we analyze EPS over a more recent period because it can provide insight into an emerging theme or development for the business. For Proto Labs, its two-year annual EPS growth of 8.2% was higher than its five-year trend. Accelerating earnings growth is almost always an encouraging data point. In Q2, Proto Labs reported adjusted EPS of $0.60, up from $0.41 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Proto Labs's full-year EPS to stay about the same, moving from $2.05 to $2.06. Key Takeaways from Proto Labs's Q2 Results We were impressed by Proto Labs's optimistic EPS guidance for next quarter, which blew past analysts' expectations. We were also excited its revenue outperformed Wall Street's estimates by a wide margin. Zooming out, we think this was a solid print. The stock traded up 2.8% to $77.28 immediately following the results. Proto Labs put up rock-solid earnings, but one quarter doesn't necessarily make the stock a buy. Let's see if this is a good investment. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it's free).

Protolabs adds new resin to its Hi-Speed SLA lineup on Axtra3D's Lumia X1. Digital manufacturing provider Protolabs has begun offering Medical White (MED-WHT 10), a biocompatible photopolymer, through its on-demand production services. The resin runs on Axtra3D's Lumia X1, a Hi-Speed SLA system built around the company's Hybrid PhotoSynthesis (HPS) process, making it the fifth production-ready material in Protolabs' Lumia X1 lineup. The launch comes as Protolabs operates three Lumia X1 units to serve orders spanning industrial and healthcare work. According to both firms, the arrangement goes further than a typical equipment sale: engineering teams on each side pinpoint promising applications together, choose candidate resins from Axtra3D's network of material suppliers, and then validate the full production workflow before anything reaches a customer. "The addition of Medical White reflects our continued commitment to providing customers with production-ready materials that solve real manufacturing challenges," said 3D Printing Director of Manufacturing Operations Kenny Capps. "Our collaboration with Axtra3D has enabled us to rapidly expand our Advanced Photopolymers offering with qualified materials that allow customers to confidently move from prototype to end-use production." What the New Material Brings to Regulated Applications Medical White targets parts where biocompatibility, sterilization compatibility, dimensional stability, and a clean visual finish are non-negotiable. The resin meets ISO 10993-5 requirements for cytotoxicity as well as ISO 10993-10 standards covering sensitization and irritation, positioning it for regulated end-use production rather than prototyping alone. Suggested use cases range from surgical guides, splints, and diagnostic components to anatomical models, dental parts, and electronics or industrial hardware that must hold tight tolerances under heat. Performance claims for the material include fine feature reproduction, accuracy that stays true to the original CAD geometry, smooth surfaces suited to presentation models, and resistance to elevated temperatures. Paired with the throughput of the HPS process, the companies say the combination supports commercial-scale output without sacrificing part detail. "This launch is an excellent example of how our Axtra Solutions business model delivers value," said Rajeev Kulkarni, Chief Strategy Officer at Axtra3D. "Our philosophy has to work with leading material innovators across the industry, selecting the best resin for each application and then partnering closely with both the material supplier and the customer to fully qualify that solution on the Lumia X1. Protolabs has become an outstanding example of how this collaborative approach accelerates adoption of additive manufacturing into production." Qualified Material Ecosystems as a Route to Production AM The Medical White launch reflects Axtra3D's broader go-to-market strategy. Instead of primarily developing chemistry in-house, the company largely sources resins from partners and qualifies each as a validated workflow under its Axtra Solutions model. Similar validation-driven material strategies have become common across resin 3D printing. Nexa3D and Henkel co-developed xMED412, a medical-grade photopolymer based on Loctite MED412, with jointly tested workflows designed to preserve the material's biocompatibility credentials on the NXE400 printer. Netherlands-based Liqcreate took an open-platform route with Bio-Med Clear, a resin passing non-cytotoxicity, non-sensitization, and non-irritation tests that is validated for autoclave sterilization, provided users follow the company's prescribed post-processing workflow. Across these efforts, the pattern is consistent: material makers, printer OEMs, and service providers increasingly ship complete, pre-qualified workflows rather than standalone resins, because medical customers buy predictability, not just chemistry. For Axtra3D and Protolabs, Medical White extends a partnership built on exactly that logic. Qualified workflows, not new machines, are now the growth engine. 3D Printing Industry is inviting speakers for its 2026 Additive Manufacturing Applications (AMA) series, covering Energy, Healthcare, Automotive and Mobility, Aerospace, Space and Defense, and Software. Each online event focuses on real production deployments, qualification, and supply chain integration. Practitioners interested in contributing can complete the call for speakers form here. Explore the full Future of 3D Printing and Executive Survey series from 3D Printing Industry, featuring perspectives from CEOs, engineers, and industry leaders on the industrialization of additive manufacturing, 3D printing industry trends 2026, qualification, supply chains, and additive manufacturing industry analysis. Featured image shows Medical White. Photo via Protolabs.